MEOBF - Mesoblast Limited

Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2022-06-30
2021-06-30
2020-06-30
2019-06-30
Total Revenue
7,657
10,211
7,456
32,156
16,722
Operating Expenses
Research Development
26,719
32,815
53,012
56,188
59,815
Selling General and Administrative
56,189
57,967
63,586
50,918
36,983
Total Operating Expenses
82,852
90,785
115,059
107,561
97,884
Operating Income or Loss
-75,195
-80,574
-107,603
-75,405
-81,162
Interest Expense
18,158
16,906
10,714
13,330
11,328
Total Other Income/Expenses Net
9,562
6,273
18,687
1,380
-6,264
Income Before Tax
-84,350
-91,586
-99,630
-87,355
-98,754
Income Tax Expense
-223
-239
-819
-9,415
-8,955
Income from Continuing Operations
-84,127
-91,347
-98,811
-77,940
-89,799
Net Income
-84,127
-91,347
-98,811
-77,940
-89,799
Net Income available to common shareholders
-84,127
-91,347
-98,811
-77,940
-89,799
Basic EPS
-
-0.14
-0.16
-0.15
-0.18
Diluted EPS
-
-0.14
-0.16
-0.15
-0.18
Basic Average Shares
-
648,900
605,064
528,822
494,381
Diluted Average Shares
-
648,900
605,064
528,822
494,381
EBITDA
-
-70,300
-88,916
-74,025
-87,426